Odyssey Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Financial Performance: Odyssey Therapeutics reported a net loss of $38.26 million for Q1 2026, translating to a loss of $6.77 per share, which is a slight improvement from last year's loss of $38.43 million or $39.37 per share, indicating minor progress in financial management.
- R&D Expenses: The company incurred R&D expenses of $32.32 million this quarter, down from $38.77 million in the same period last year, reflecting effective cost control that may enhance future funding allocation for critical projects.
- Successful IPO: Odyssey completed its initial public offering with gross proceeds of $314.8 million, beginning trading on the Nasdaq Capital Market on May 8, 2026, which strengthens its capital base to support ongoing research and development efforts.
- Clinical Progress: The Phase 2a study for OD-001 was successfully concluded, demonstrating proof-of-concept for ulcerative colitis treatment, with plans to advance to a Phase 2b trial in the second half of 2026, and topline data expected in the second half of 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ODTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ODTX
Wall Street analysts forecast ODTX stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 18.480
Low
Averages
High
Current: 18.480
Low
Averages
High
About ODTX
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its advanced programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. These programs have the potential to yield treatments for inflammatory and autoimmune diseases. In addition to its advanced programs, it has a portfolio of preclinical programs that include a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated kinase 4, or IRAK4, scaffolding inhibitor. It also has an interferon regulatory factor 5, or IRF5, inhibitor in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Odyssey Therapeutics Reports Positive Clinical Data for OD-001
- Clinical Trial Progress: Odyssey Therapeutics achieved positive proof-of-concept for OD-001 in a Phase 2a monotherapy trial, with 27% of the 49 patients achieving clinical remission and 61% showing clinical response after 12 weeks, indicating good tolerability and efficacy in moderate-to-severe ulcerative colitis patients.
- Financing Situation: As of March 31, 2026, the company had $175.7 million in cash and cash equivalents, with net proceeds from the IPO and private placement expected to total $464 million, which will fund operations into the second half of 2028, ensuring continued investment in R&D.
- Future Development Plans: Odyssey plans to initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, with topline data from both trials expected in the second half of 2027, further advancing its treatment options in inflammatory bowel disease.
- Financial Performance: Research and development expenses for Q1 2026 were $32.3 million, down from $38.8 million in Q1 2025, primarily due to a non-cash lease impairment charge, while the net loss was $38.3 million, reflecting the company's efforts to control costs.
See More
Odyssey Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
- Financial Performance: Odyssey Therapeutics reported a net loss of $38.26 million for Q1 2026, translating to a loss of $6.77 per share, which is a slight improvement from last year's loss of $38.43 million or $39.37 per share, indicating minor progress in financial management.
- R&D Expenses: The company incurred R&D expenses of $32.32 million this quarter, down from $38.77 million in the same period last year, reflecting effective cost control that may enhance future funding allocation for critical projects.
- Successful IPO: Odyssey completed its initial public offering with gross proceeds of $314.8 million, beginning trading on the Nasdaq Capital Market on May 8, 2026, which strengthens its capital base to support ongoing research and development efforts.
- Clinical Progress: The Phase 2a study for OD-001 was successfully concluded, demonstrating proof-of-concept for ulcerative colitis treatment, with plans to advance to a Phase 2b trial in the second half of 2026, and topline data expected in the second half of 2027.
See More
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Odyssey and Mobia Stocks Plummet After IPOs Raising Over $450M
- Odyssey IPO Performance: Odyssey Therapeutics (ODTX) raised approximately $304 million in its IPO, opening at $20, an 11% increase from its $18 offering price, but by 2 PM ET, the stock had declined to $16.49, reflecting an 8% pullback that raises concerns about its long-term growth potential.
- Mobia Stock Fluctuation: Mobia Medical (MOBI) raised $150 million in its IPO, opening at $14, down 7% from its $15 offering price, and further dropped to $11.49 by 2:10 PM ET, indicating a 23% decline, suggesting a lack of investor confidence in its market outlook.
- Market Reaction Analysis: Both companies experienced significant stock price declines post-IPO, indicating that despite raising over $450 million, the market remains cautious about the short-term performance of the biotech and MedTech sectors, which could impact future fundraising capabilities.
- Investor Confidence Challenge: The IPO performances of Odyssey and Mobia reflect a testing of investor confidence in newly listed companies, particularly in the current economic climate, which may lead to diminished interest in similar firms in the future.
See More
Odyssey Therapeutics Raises $25 Million in Private Placement
- Funding Details: Odyssey Therapeutics successfully raised $25 million through a private placement of 1.39 million shares to an affiliate of TPG Life Sciences Innovations, enhancing its financial capacity to support ongoing research and development.
- Drug Development Plans: The company intends to use the proceeds to advance the development of OD-001, its leading drug candidate for ulcerative colitis and Crohn's disease, while also progressing the SLC15A4 program and other clinical activities.
- IPO Performance: Odyssey Therapeutics debuted on Nasdaq at $20 per share, achieving a valuation of $900 million, although the stock has since fallen to $16 per share, representing a nearly 10% decline from its issue price of $18.
- Financial Status: As of March 31, 2026, the company reported $175.7 million in cash and marketable securities, despite a net loss of $148.6 million in 2025, indicating ongoing financial pressure from its research investments.
See More
Odyssey Therapeutics Reports Positive Clinical Data for OD-001
- Clinical Trial Progress: Odyssey Therapeutics achieved positive proof-of-concept for OD-001 in a Phase 2a monotherapy trial, with 27% of the 49 patients achieving clinical remission and 61% showing clinical response after 12 weeks, indicating good tolerability and efficacy in moderate-to-severe ulcerative colitis patients.
- Financing Situation: As of March 31, 2026, the company had $175.7 million in cash and cash equivalents, with net proceeds from the IPO and private placement expected to total $464 million, which will fund operations into the second half of 2028, ensuring continued investment in R&D.
- Future Development Plans: Odyssey plans to initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, with topline data from both trials expected in the second half of 2027, further advancing its treatment options in inflammatory bowel disease.
- Financial Performance: Research and development expenses for Q1 2026 were $32.3 million, down from $38.8 million in Q1 2025, primarily due to a non-cash lease impairment charge, while the net loss was $38.3 million, reflecting the company's efforts to control costs.
See More
Odyssey Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
- Financial Performance: Odyssey Therapeutics reported a net loss of $38.26 million for Q1 2026, translating to a loss of $6.77 per share, which is a slight improvement from last year's loss of $38.43 million or $39.37 per share, indicating minor progress in financial management.
- R&D Expenses: The company incurred R&D expenses of $32.32 million this quarter, down from $38.77 million in the same period last year, reflecting effective cost control that may enhance future funding allocation for critical projects.
- Successful IPO: Odyssey completed its initial public offering with gross proceeds of $314.8 million, beginning trading on the Nasdaq Capital Market on May 8, 2026, which strengthens its capital base to support ongoing research and development efforts.
- Clinical Progress: The Phase 2a study for OD-001 was successfully concluded, demonstrating proof-of-concept for ulcerative colitis treatment, with plans to advance to a Phase 2b trial in the second half of 2026, and topline data expected in the second half of 2027.
See More
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Odyssey and Mobia Stocks Plummet After IPOs Raising Over $450M
- Odyssey IPO Performance: Odyssey Therapeutics (ODTX) raised approximately $304 million in its IPO, opening at $20, an 11% increase from its $18 offering price, but by 2 PM ET, the stock had declined to $16.49, reflecting an 8% pullback that raises concerns about its long-term growth potential.
- Mobia Stock Fluctuation: Mobia Medical (MOBI) raised $150 million in its IPO, opening at $14, down 7% from its $15 offering price, and further dropped to $11.49 by 2:10 PM ET, indicating a 23% decline, suggesting a lack of investor confidence in its market outlook.
- Market Reaction Analysis: Both companies experienced significant stock price declines post-IPO, indicating that despite raising over $450 million, the market remains cautious about the short-term performance of the biotech and MedTech sectors, which could impact future fundraising capabilities.
- Investor Confidence Challenge: The IPO performances of Odyssey and Mobia reflect a testing of investor confidence in newly listed companies, particularly in the current economic climate, which may lead to diminished interest in similar firms in the future.
See More
Odyssey Therapeutics Raises $25 Million in Private Placement
- Funding Details: Odyssey Therapeutics successfully raised $25 million through a private placement of 1.39 million shares to an affiliate of TPG Life Sciences Innovations, enhancing its financial capacity to support ongoing research and development.
- Drug Development Plans: The company intends to use the proceeds to advance the development of OD-001, its leading drug candidate for ulcerative colitis and Crohn's disease, while also progressing the SLC15A4 program and other clinical activities.
- IPO Performance: Odyssey Therapeutics debuted on Nasdaq at $20 per share, achieving a valuation of $900 million, although the stock has since fallen to $16 per share, representing a nearly 10% decline from its issue price of $18.
- Financial Status: As of March 31, 2026, the company reported $175.7 million in cash and marketable securities, despite a net loss of $148.6 million in 2025, indicating ongoing financial pressure from its research investments.
See More
